Allergan (AGN) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Allergan's (AGN) Quarter Not Strong Enough to Support Price Target - PiperJaffray
February 23, 2016 8:23 AM ESTAllergan (NYSE: AGN) posted a solid 4Q leading Piper Jaffray analyst, David Amsellem, to reiterate his Overweight rating but trim his price target as estimates roll forward.
AGN reported non-GAAP diluted EPS of $3.41 on revenues of $4.2B, versus the Street estimates of $3.36 and $4.2B. Performance across several key product franchises remained strong, with total brand revenue in 4Q15 growing by 11% over 4Q14 (excluding foreign exchange headwinds and the erosion of the immediate-release form of Namenda due to generics).
The company has strong visibility on continued brisk volume growth for key... More
Mizuho Securities Reiterates Buy on Allergan (AGN) Following a 4Q Earnings Beat
February 23, 2016 7:04 AM ESTMizuho Securities maintained a Buy rating on Allergen (NYSE: AGN), and cut the price target to $330.00 (from $354.00), following the company's 4Q earnings report. AGN delivered a solid 4Q bottom line beat with revenues of $4.2B and EPS of $3.41 versus consensus estimates $4.2B and... More
